BIIB: Biogen Inc. Stocks News on April 30, 2025

BIIB

Thomson Reuters StreetEvents

12 hours ago

Q1 2025 SAGE Therapeutics Inc Earnings Call

BIIB

StockStory

17 hours ago

Biogen Earnings: What To Look For From BIIB

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

BIIB

Zacks

a day ago

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

BIIB

Zacks

2 days ago

The Zacks Analyst Blog Highlights Pfizer, Eli Lilly, Amgen, Biogen and Regeneron

BIIB

MT Newswires

2 days ago

Piper Sandler Adjusts Price Target on Biogen to $115 From $135, Maintains Neutral Rating

BIIB

MT Newswires

2 days ago

Truist Securities Adjusts Price Target on Biogen to $199 From $210, Maintains Buy Rating

BIIB

MT Newswires

3 days ago

HSBC Downgrades Biogen to Hold From Buy, Adjusts Price Target to $118 From $342

BIIB

MT Newswires

6 days ago

RBC Cuts Price Target on Biogen to $217 From $225, Keeps Outperform Rating

BIIB

Zacks

6 days ago

Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

BIIB

StockStory

6 days ago

1 Safe-and-Steady Stock with Promising Prospects and 2 to Ignore

Can Biogen Keep the Beat Streak Alive This Earnings Season?

BIIB

Zacks

7 days ago

Can Biogen Keep the Beat Streak Alive This Earnings Season?

Biogen’s Friedreich’s ataxia treatment authorised in UK

BIIB

Pharmaceutical Technology

7 days ago

Biogen’s Friedreich’s ataxia treatment authorised in UK

BIIB

MT Newswires

7 days ago

Goldman Sachs Adjusts Price Target on Biogen to $197 From $219, Maintains Buy Rating

BIIB

MT Newswires

8 days ago

RBC Lifts Price Target on Biogen to $225 From $221, Keeps Outperform Rating

BIIB

MT Newswires

13 days ago

BMO Capital Adjusts Biogen Price Target to $128 From $139

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

BIIB

Zacks

14 days ago

Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s

BIIB

Pharmaceutical Technology

14 days ago

EC authorises Eisai and Biogen’s lecanemab for Alzheimer’s

BIIB

Associated Press Finance

14 days ago

European regulators OK Alzheimer's treatment Leqembi after initial doubts

BIIB

MT Newswires

14 days ago

Wedbush Cuts Biogen Price Target to $121 From $135, Maintains Neutral Rating

BIIB

MT Newswires

15 days ago

Update: Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

BIIB

GlobeNewswire

15 days ago

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

BIIB

MT Newswires

15 days ago

Biogen, Eisai's Alzheimer's Drug Leqembi Approved in EU

BIIB

MT Newswires

15 days ago

Goldman Sachs Adjusts Biogen's Price Target to $219 From $245, Keeps Buy Rating

BIIB

MT Newswires

17 days ago

Goldman Sachs Cuts Price Target on Biogen to $219 From $245

BIIB

MT Newswires

19 days ago

Citigroup Adjusts Price Target on Biogen to $125 From $145, Keeps Neutral Rating

BIIB

Clinical Trials Arena

20 days ago

Alzheon’s Alzheimer’s pill fails in Phase III trial

BIIB

MT Newswires

20 days ago

Guggenheim Adjusts Price Target on Biogen to $165 From $190, Maintains Buy Rating

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

BIIB

Investor's Business Daily

20 days ago

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

BIIB

Zacks

20 days ago

Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock?

BIIB

MT Newswires

21 days ago

Morgan Stanley Adjusts Price Target on Biogen to $152 From $157, Keeps Equalweight Rating

BIIB

Morningstar Research

a month ago

Analyst Report: Biogen Inc.

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

BIIB

Investor's Business Daily

a month ago

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

BIIB

MT Newswires

a month ago

Argus Downgrades Biogen to Hold From Buy

BIIB

Argus Research

a month ago

Market Digest: APD, BIIB, BJ, CNP, FE

BIIB

Simply Wall St.

a month ago

Biogen (NasdaqGS:BIIB) Gets US FDA Fast Track For Alzheimer's Despite US$8M Settlement

BIIB

Zacks

a month ago

BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag

BIIB

MT Newswires

a month ago

RBC Trims Price Target on Biogen to $221 From $225, Keeps Outperform Rating

Organon acquires Actemra biosimilar’s US rights from Biogen

BIIB

Pharmaceutical Technology

a month ago

Organon acquires Actemra biosimilar’s US rights from Biogen

BIIB

MT Newswires

a month ago

Biogen Says Investigational Alzheimer's Drug Receives FDA Fast Track Designation

BIIB

GlobeNewswire

a month ago

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease

BIIB

MT Newswires

a month ago

Organon Acquires Tofidence for Intravenous Infusion in US

BIIB

Simply Wall St.

a month ago

Biogen (NASDAQ:BIIB) sheds US$697m, company earnings and investor returns have been trending downwards for past five years

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

BIIB

BioPharma Dive

a month ago

Lilly hits same Alzheimer’s roadblock in Europe as Eisai, Biogen

BIIB

MT Newswires

a month ago

Biogen Signs Lease for New Global HQ in Cambridge, Massachusetts

BIIB

StockStory

a month ago

3 Value Stocks Walking a Fine Line

Biogen plots new global headquarters in Kendall Square

BIIB

BioPharma Dive

a month ago

Biogen plots new global headquarters in Kendall Square

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

BIIB

GlobeNewswire

a month ago

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

BIIB

Zacks

a month ago

Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound?

BIIB

StockStory

a month ago

Q4 Rundown: Biogen (NASDAQ:BIIB) Vs Other Therapeutics Stocks

BIIB

Insider Monkey

a month ago

Biogen Inc. (BIIB): Among the Most Undervalued Biotech Stocks to Invest In

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia

BIIB

Pharmaceutical Technology

a month ago

Health Canada approves Biogen’s Skyclarys for Friedreich’s ataxia

BIIB

Zacks

2 months ago

Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?

BIIB

Zacks

2 months ago

Can BIIB's New Drugs Revive Growth as Multiple Sclerosis Sales Fall?

BIIB

Zacks

2 months ago

BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

BIIB

BioPharma Dive

2 months ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

BIIB

Clinical Trials Arena

2 months ago

Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR

BIIB

MT Newswires

2 months ago

Biogen Initiates Dosing of Phase 3 Study of Felzartamab

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

BIIB

GlobeNewswire

2 months ago

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion?

BIIB

Investor's Business Daily

2 months ago

Is Eli Lilly Stock A Buy As It Plays Ball With Trump To The Tune Of $27 Billion?

Tariffs Send Investors to Safety of Food, Drug and Utility Stocks

BIIB

The Wall Street Journal

2 months ago

Tariffs Send Investors to Safety of Food, Drug and Utility Stocks

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

BIIB

Pharma Voice

2 months ago

New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach

BIIB

MT Newswires

2 months ago

Biogen's Alzheimer's Treatment Lecanemab Denied Approval in Australia

BIIB

StockStory

2 months ago

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

BIIB

MT Newswires

2 months ago

Biogen, Eisai Say EMA Panel Reaffirms Positive Opinion on Lecanemab

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

BIIB

PR Newswire

2 months ago

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer's Disease

BIIB

Insider Monkey

2 months ago

Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

BIIB

Benzinga

2 months ago

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

BIIB

Insider Monkey

2 months ago

Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

BIIB

Pharmaceutical Technology

2 months ago

Biogen and Stoke Therapeutics to commercialise Dravet syndrome treatment

BIIB

Simply Wall St.

2 months ago

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

BIIB

Benzinga

2 months ago

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

BIIB

MT Newswires

2 months ago

Bernstein Adjusts Price Target on Biogen to $159 From $160, Keeps Market Perform Rating

BIIB

MT Newswires

2 months ago

Piper Sandler Adjusts Price Target on Biogen to $135 From $138, Keeps Neutral Rating

BIIB

MT Newswires

2 months ago

Biogen, Stoke Partner on Dravet Syndrome Investigational Drug Zorevunersen

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

BIIB

Business Wire

2 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

Biogen buys rights to Stoke’s rare epilepsy drug

BIIB

BioPharma Dive

2 months ago

Biogen buys rights to Stoke’s rare epilepsy drug

BIIB

MT Newswires

2 months ago

Guggenheim Cuts Biogen Price Target to $168 From $190

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

BIIB

Benzinga

3 months ago

Leqembi And Skyclarys Expected To Drive Biogen's Future Growth: Analysts

BIIB

MT Newswires

3 months ago

Biogen Still Offering Value, RBC Says

BIIB

Zacks

3 months ago

Biotech Stock Roundup: GILD Up on Q4 Results, BIIB, BMY Down on 2025 Guidance

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

BIIB

TipRanks

3 months ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

BIIB

BioPharma Dive

3 months ago

Neumora shakes up its C-suite; Biogen cuts early-stage pipeline

BIIB

MT Newswires

3 months ago

Truist Securities Adjusts Price Target on Biogen to $210 From $220, Keeps Buy Rating

BIIB

MT Newswires

3 months ago

Scotiabank Adjusts Biogen Price Target to $224 From $244

BIIB

MT Newswires

3 months ago

Wedbush Adjusts Biogen Price Target to $135 From $166

Biogen expects 2025 profit decline despite strong Q4

BIIB

Yahoo Finance Video

3 months ago

Biogen expects 2025 profit decline despite strong Q4

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

BIIB

Benzinga

3 months ago

Biogen Q4 Earnings: Revenue And EPS Beat, Warns Lower 2025 Revenue, Inks R&D Funding Pact With Royalty Pharma

BIIB

MT Newswires

3 months ago

Royalty Pharma to Provide up to $250 Million to Biogen for Litifilimab R&D

BIIB

Zacks

3 months ago

Biogen Inc. (BIIB) Q4 Earnings and Revenues Surpass Estimates

BIIB

StockStory

3 months ago

Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates

BIIB

MT Newswires

3 months ago

Biogen's Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition

BIIB

Reuters

3 months ago

Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition

Why Investors Might Hammer Biogen Despite Its Earnings Beat

BIIB

Investor's Business Daily

3 months ago

Why Investors Might Hammer Biogen Despite Its Earnings Beat

BIIB

Investing.com

3 months ago

Bernstein starts Biogen at ‘market-perform,’ notes near term uncertainty

BIIB

StockStory

3 months ago

Biogen (BIIB) Reports Earnings Tomorrow: What To Expect

BIIB

MT Newswires

3 months ago

Bernstein Initiates Biogen at Market Perform With $160 Price Target

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

BIIB

Zacks

3 months ago

Will These 5 Biotech Bigwig Stocks Surpass Q4 Earnings Forecast?

BIIB

Insider Monkey

3 months ago

Why Biogen Inc. (BIIB) Is Among the Best Healthcare Stocks To Buy According to Analysts

BIIB

Zacks

3 months ago

Latest Biogen Inc. (BIIB) News on April 30, 2025

Share on Social Networks: